Heparin Dosing for Acute Limb Ischemia
For acute limb ischemia, immediately administer unfractionated heparin as an intravenous bolus of 5,000 IU (or 70-100 IU/kg, maximum 5,000 IU) followed by continuous infusion, unless contraindications exist. This should be given upon clinical diagnosis, before any imaging or revascularization planning 1, 2.
Initial Dosing Regimen
The standard approach uses weight-based dosing with unfractionated heparin (UFH):
- Bolus: 80 units/kg IV (or fixed dose of 5,000 units)
- Continuous infusion: 18 units/kg/hour (or 20,000-40,000 units/24 hours)
- Target aPTT: 1.5 to 2.5 times control (corresponding to anti-Factor Xa level of 0.3-0.7 IU/mL)
The FDA-approved dosing for therapeutic anticoagulation specifies either the weight-based approach (80 units/kg bolus, 18 units/kg/hour infusion) or a fixed-dose regimen (5,000 unit bolus followed by at least 32,000 units/day) 4. The weight-based approach is preferred because it achieves therapeutic anticoagulation more rapidly—critical in ALI where delays increase amputation and mortality risk 3.
Alternative: Subcutaneous Administration
If IV access is problematic or continuous infusion monitoring unavailable:
- Initial IV bolus: 5,000 units
- Subcutaneous: 250 units/kg twice daily
OR
- Initial subcutaneous dose: 333 units/kg
- Maintenance: 250 units/kg twice daily
Monitoring Requirements
Check aPTT every 4 hours initially until therapeutic range achieved, then at appropriate intervals 4. The therapeutic window (aPTT 1.5-2.5 times control) prevents both thrombus propagation and excessive bleeding risk 3, 6.
Monitor platelet counts every 2-3 days from day 4 to day 14 to screen for heparin-induced thrombocytopenia (HIT), which occurs in up to 5% of patients receiving UFH 5. This is particularly important in ALI as HIT can cause paradoxical thrombosis.
Rationale and Evidence Strength
The 2024 ESC guidelines explicitly state that patients with ALI should receive anticoagulation immediately upon diagnosis to prevent thrombus propagation and distal embolization 1. The 2024 ACC/AHA guidelines similarly mandate systemic anticoagulation with UFH for all ALI patients regardless of anatomic level or cause, unless contraindicated 2.
UFH is preferred over LMWH or other anticoagulants in ALI because of its short half-life and immediate reversibility—essential when urgent revascularization procedures may be needed 1, 2. The drug can be stopped quickly if bleeding occurs or surgery becomes necessary.
Weight-based dosing achieves therapeutic anticoagulation faster than fixed dosing. In the landmark Raschke study, patients receiving weight-adjusted heparin (80 units/kg bolus, 18 units/kg/hour) had significantly lower recurrent thromboembolism rates compared to fixed-dose regimens 3.
Clinical Pitfalls to Avoid
Do not delay heparin for imaging studies. Anticoagulation should begin immediately upon clinical diagnosis—before angiography, before determining revascularization strategy 7, 1, 2. Every hour of delay increases risk of irreversible ischemia.
Do not use prophylactic doses. The 5,000 units every 8-12 hours regimen is for DVT prophylaxis, not therapeutic anticoagulation in ALI 4. This underdosing increases recurrence rates 3.
Avoid intramuscular administration due to hematoma risk 4.
Do not routinely add intra-arterial heparin during catheter-directed thrombolysis. Recent evidence shows this increases bleeding complications (44.2% vs 21.1%) without improving procedural success 8. The systemic IV heparin is sufficient.
Special Populations
Renal impairment (CrCl <30 mL/min): UFH is preferred over LMWH as it doesn't accumulate 5.
History of HIT: Use a direct thrombin inhibitor (bivalirudin) instead of heparin 2.
Patients on warfarin with subtherapeutic INR: Still give full-dose heparin—the INR doesn't provide adequate anticoagulation for acute arterial thrombosis 6.
Duration of Therapy
Continue heparin until definitive revascularization is completed or until transitioning to oral anticoagulation if revascularization isn't pursued 1, 2. For patients undergoing surgical intervention, heparin provides a bridge and can be stopped perioperatively given its short half-life.
The evidence consistently shows that immediate, aggressive anticoagulation with properly dosed heparin reduces amputation rates and mortality in ALI 9, 10, 11. Patients achieving therapeutic aPTT within 24 hours have significantly lower in-hospital and 30-day mortality compared to those with delayed therapeutic anticoagulation 3.